Got 90 seconds? Then listen to managing director and CEO Mark Diamond tell us about Antisense Therapeutics.

Antisense (ASX:ANP) is an Australian biopharma drug discovery and development company focused on creating, developing and commercialising novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy, Multiple Sclerosis, and Acromegaly.

We gave the company’s managing director and CEO, Mark Diamond, 90 Seconds to provide and overview of Antisense, its recent drug developments and near term newsflow.

Note: Since the recording of this interview, Antisense has announced positive early results from the clinical trial of its ATL1102 drug.

Have a good idea for our next 90 Seconds With segment? Email us at tv@stockhead.com.au.